BGC
ICPT

Birch Grove Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Birch Grove Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,200
Closed -$257K – 53
2020
Q3 		$257K Buy
+6,200
New +$285K 0.14% 45

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Birch Grove Capital's ICPT Position: Q4 2020 in Review

Birch Grove Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2020, closing a stake of 6,200 shares — an estimated $257K sold.

Birch Grove Capital first reported a position in ICPT in Q3 2020 and held it in 1 quarter. The position peaked at $257K in Q3 2020. 175 funds tracked by Wall St. Rank hold ICPT as of Q4 2020.

  • Birch Grove Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Birch Grove Capital sold 6,200 Intercept Pharmaceuticals, Inc. shares in Q4 2020, an estimated $257K.
  • Birch Grove Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2020 and held it in 1 quarter.
  • Birch Grove Capital's Intercept Pharmaceuticals, Inc. position peaked at $257K in Q3 2020.
  • 175 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2020.

Based on Birch Grove Capital's 13F filing for Q4 2020, filed 16 Feb 2021.